27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Quest Diagnostics Incorporated (NYSE:DGX) posted better-than-expected second-quarter results, as vaccinations and the lifting of lockdowns resulted in recovery in its core non-coronavirus testing businesses.
- Q2 adjusted EPS surged almost 125% Y/Y at $3.18, beating the consensus estimate of $2.86.
- Sales came in at $2.6 billion, increased 40% Y/Y, and higher than the Wall Street estimate of $2.4 billion.
- Q2 revenue from the diagnostic information services business, which provides tests for cancer, cardiovascular diseases, infectious diseases, and neurology, was up 40% to $2.6 billion.
- Quest's rival Abbott Laboratories (NYSE:ABT) recorded improvements in its non-COVID-19 businesses as vaccinated Americans become more comfortable visiting doctors.
- "This was the first quarter since 2019 that organic base testing revenues grew in the quarter," Chief Executive Officer Steve Rusckowski said in a statement.
- Outlook: Banking on the improvements, Quest forecast full-year revenue of $9.54 billion - $9.79 billion, higher than the analyst consensus of $9.45 billion.
- It also estimated annual adjusted EPS of $10.65 and $11.35, the mid-pint being lower than the Wall Street estimate of $11.13.
- Price Action: DGX shares are down 0.57% at $135 during the premarket session on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!